Aprogen Biologics
Key metrics
Earnings
| Revenue, Q3 2026 | ₩23.2bn |
|---|---|
| Revenue QoQ | +0.5% |
| Revenue YoY | +9.8% |
| Operating income, Q3 2026 | -₩7.5bn |
| Operating income QoQ | +56.9% |
| Operating income YoY | +29.5% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩60.8bn |
|---|---|
| Rights offering new shares, last 12 months | 14,386,622 shares |
| Potential new shares, last 12 months | 38,231,890 shares |
| Potential new shares, % of shares | 265.3% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 17 |
|---|---|
| DART filings, previous 3 months | 22 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Exercise price adjustment) | +147,484 shares | ₩2,948 | ₩435m | |
| Sep 23, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Paid-in new shares) | +12,706,481 shares | ₩1,574 | ₩20.0bn | |
| Aug 29, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Exercise price adjustment) | +972,952 shares | ₩3,082 | ₩3.0bn | |
| Jul 28, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Third-party placement) | +1,087,548 shares | — | — | |
| Jul 28, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Exercise price adjustment) | +15,886 shares | — | — | |
| May 29, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Convertible bond acquisition) | +2,255,808 shares | — | — | |
| Apr 28, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Paid-in new shares) | +592,593 shares | — | — | |
| Apr 16, 2026 | G-BAISE Inc. (Controlling shareholder) | Other (Reverse split) | -47 shares | — | — | |
| Apr 15, 2026 | Aprogen,Inc. (10%+ shareholder) | Other (Capital reduction) | -105,308,856 shares | — | — | |
| Apr 15, 2026 | Kim Jeong-chul (Registered director) | Other (Capital reduction) | -20,422 shares | — | — | |
| Apr 15, 2026 | Kang Seong-ho (Registered director) | Other (Capital reduction) | -11,541 shares | — | — | |
| Apr 15, 2026 | Kim An-su (Non-registered officer) | Other (Capital reduction) | -4,493 shares | — | — | |
| Apr 15, 2026 | Kim Yong-u (Non-registered officer) | Other (Capital reduction) | -2,196 shares | — | — | |
| Apr 15, 2026 | Na O-seong (Non-registered officer) | Other (Capital reduction) | -12,156 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩73.2bn | -₩60.4bn |
| 2024 | ₩67.4bn | -₩52.8bn |
| 2023 | ₩87.4bn | -₩57.5bn |